IDEV Technologies Launches Additional Products in Europe

New Sizes of SUPERA(R) Stent Expand Treatment Options for Peripheral Vascular Disease

WEBSTER, Texas, October 21, 2010 - IDEV Technologies, Incorporated (IDEV), an innovative leader in the
development and commercialization of minimally invasive medical technologies,
today announced another step in the implementation of its strategy to expand
its product line for treating patients with peripheral vascular disease with
the addition of two longer stents to its SUPERA product line. The initial
uses of the newly introduced 180mm and 200mm stents occurred in August of
this year, followed by a full European market launch at the recent European
Society of Vascular Surgery meeting held this past September, in Amsterdam.

SUPERA stents are well known for their radial strength and flexibility
that results from the unique wire interwoven nitinol design, which also
provides high resistance to kinking/fracturing. The new 180mm and 200mm sizes
are designed for the treatment of long lesions in patients with peripheral
vascular disease.

"We are very pleased with the acceptance of these new longer stents. Our
goal is to provide the broadest and most effective line of products for
treating patients with peripheral vascular disease. The successful launch of
these additional SUPERA sizes moves us closer to reaching that goal and
achieves our objective of launching multiple new products in Europe this
year," stated Christopher M. Owens, President and CEO of IDEV.

The launch of these devices follows the recent introduction of the SUPERA
VERITAS(TM) Peripheral Vascular System, an easy to use, reliable and more
precise delivery system developed to deliver the SUPERA stent.

Peter Haarbrink, MD, a leading interventional radiologist affiliated with
Canisius Wilhelmina Ziekenhuis (CWZ), a large general and teaching hospital
located in Nijmegen, The Netherlands, said, "The availability of these new
sizes has given me even more options for treating patients with peripheral
vascular disease. The unique and exceptional stent properties, combined with
the ease of delivery with the new VERITAS(TM) system, create a true
advancement in technology."

Dierk Scheinert, MD, and Chairman of the Center for Vascular Medicine at
the Park Hospital, Leipzig, Germany, was one of the first to deploy the
longer sizes. He concluded, "I've used the SUPERA product for several years
and appreciate the ongoing enhancements to the system. First VERITAS made it
easier and more accurate to deploy the stent. Now the 180mm and 200mm sizes
allow me to treat longer and more difficult lesions, they deploy easily and
add to a broad stent portfolio."

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of
next generation medical devices for use in the interventional radiology,
vascular surgery and cardiology marketplace. IDEV's worldwide headquarters is
located in Webster, Texas and its European headquarters is located in
Beuningen, The Netherlands. Please visit www.idevmd.com.

The SUPERA stent is currently indicated in the US for the palliative
treatment of biliary strictures produced by malignant neoplasms and in Europe
for both the treatments of biliary strictures produced by malignant neoplasms
and for peripheral vascular use following failed percutaneous transluminal
angioplasty (PTA).

    Contact: William W. Burke
             Executive Vice President & Chief Financial Officer
             IDEV Technologies, Incorporated
             +1-281-525-2000

             Donna Lucchesi
             Vice President Global Marketing
             IDEV Technologies, Incorporated
             +1-281-525-2000

William W. Burke, Executive Vice President & Chief Financial Officer, or Donna Lucchesi, Vice President Global Marketing, both of IDEV Technologies, Incorporated, +1-281-525-2000